Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.-Reference-Cited by-同舟云学术

Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:2535-2535
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Siu Lillian L.¹,Italiano Antoine²,Miller Wilson H.³,Blay Jean-Yves⁴,Gietema Jourik A.⁵,Bang Yung-Jue⁶,Mileshkin Linda R.⁷,Hirte Hal W.⁸,Reckner Monica⁹,Higgins Brian¹⁰,Jukofsky Lori¹¹,Blotner Steven¹²,Zhi Jianguo¹²,Middleton Steven¹⁰,Nichols Gwen L.¹⁰,Chen Lin Chi¹⁰

Affiliation:

1. Princess Margaret Cancer Centre, Toronto, ON, Canada

2. Institut Bergonié, Bordeaux, France

3. Segal Cancer Center, Jewish General Hospital, Department of Oncology, McGill University, Montreal, QC, Canada

4. Centre Léon Bérard, Lyon, France

5. Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands

6. Department of Internal Medicine and Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea

7. Peter MacCallum Cancer Center, Melbourne, Australia

8. Juravinski Cancer Centre, Hamilton, ON, Canada

9. Hoffmann-La Roche, Translational and Clinical Research Center, New York, NY

10. Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, New York, NY

11. Hoffmann-La Roche, Translational Clinical Research Center, Oncology Translational Medicine, New York, NY

12. Hoffmann-La Roche Inc., Translational Clinical Research Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.2535

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation;Biomedicines;2023-07-02

2. Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy;Nature Communications;2023-04-06

3. Therapeutic Strategies to Activate p53;Pharmaceuticals;2022-12-24

4. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity;Frontiers in Oncology;2022-08-04

5. Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials;Journal of Hematology & Oncology;2022-07-13